PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

[News]

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

More... (https://www.news-medical.net/news/20180702/PMDA-approves-use-of-LYNPARZA-in-patients-with-BRCA-mutated-breast-cancer.aspx)